Von Hippel Lindau Syndrome-Associated Clear Cell Renal Cell Carcinoma

Von Hippel Lindau Syndrome-Associated Clear Cell Renal Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

2 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2
Recruiting: 1
Ph III recruiting: 0
Growth YoY: —
Industry share: 100%
Top sponsor: Neomorph, Inc
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (0)

clinicaltrialsPublishedShowing 1–2 of 2 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07300241	Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma	recruiting	Phase 1	30	Neomorph, IncINDUSTRY	1	Aug 3, 2026	clinicaltrials
NCT03401788	A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)	active not recruiting	Phase 2	50	Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY